The recently communicated partner agreement with Tempus AI in the U.S. and the agreement with a leading healthcare provider, which was communicated in December 2024, are expected to generate significant revenues for Biovica. Along with more than 15 active collaborations with pharmaceutical companies representing a total project value of approximately 25 MSEK and the 18 active partnership agreements covering key European markets, the company has established a strong foundation for growth. On this basis, Biovica is now in a position to provide clear financial guidance.

Biovica’s financial targets:

• FY 2024/25 (ending April 30, 2025): Net sales of SEK 8.5 million
• FY 2025/26: Net sales of SEK 50 million
• FY 2026/27: Net sales of SEK 150 million

With expected operating expenses at the current level of approximately 90 MSEK per year, Biovica anticipates becoming cash-flow positive during the third quarter of FY 2026/27.

The expected distribution of revenues during FY25/26 and FY 26/27 are:

• 65% from the U.S. market, driven by reimbursement and volume growth through strategic partnerships
• 30% from pharma services, based on ongoing and future biomarker collaborations
• 5% from European partners, through distributor and lab agreements across 18 territories

“These targets reflect the solid groundwork we have laid over the past years,” says Anders Rylander, CEO of Biovica. “We’ve achieved clinical validation through world-leading oncologists and institutions, received FDA clearance, established a CMS/Medicare price, initiated commercial sales, and now secured strategic partnerships that enable us to scale up. The pieces are in place to deliver on our vision—improving outcomes for patients, optimizing care for providers, and generating long-term value for shareholders.”